A vaccine administered during pregnancy is substantially lowering hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a reduction of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and passing protection through the placenta. A significant recent study examining nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the timeframe when infants are most vulnerable to the virus. RSV affects roughly half of all newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases recorded annually across the UK.
How the immunisation safeguards at-risk babies
RSV, or respiratory syncytial virus, is a common respiratory infection that affects approximately half of all newborns during their first few months of life. The virus can range from causing mild cold-like symptoms to triggering severe chest infections that cause babies to struggle to breathe and feed. In the most severe cases, the lung inflammation becomes life-threatening, with small numbers of babies dying from the infection annually. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the deeply distressing nature of serious RSV infections: “In babies with bad infections you can see their chest and lungs struggling, as they try to pull enough oxygen in. This is very, very frightening as a parent, frightening for good reason.”
The pregnancy vaccine functions by stimulating the mother’s body’s defences to produce protective antibodies, which are then transferred to the developing baby through the placenta. This maternal immunity offers newborns with instant defence from the moment of birth, precisely when they are highly susceptible to RSV. The latest research demonstrates that protection reaches approximately 85% when the vaccine is given four weeks or more before delivery. Even shorter intervals between vaccination and birth can still provide meaningful protection, with evidence indicating that a two-week gap is adequate to shield babies born slightly early. Dr Watson recommends pregnant women to receive the vaccine at the recommended time, whilst observing that protection remains possible even if administered later in the third trimester.
- Nearly 85 per cent protection when vaccinated four weeks before birth
- Maternal antibodies passed through placenta protect newborns from birth
- Protection possible with 2-week gap before early delivery
- Vaccination in the third trimester still offers meaningful infant protection
Compelling evidence from current research
The performance of the pregnancy RSV vaccine has been confirmed through a comprehensive study carried out throughout England, analysing data from close to 300,000 babies born between September 2024 and March 2025. This constitutes approximately 90% of all births during that six-month period, providing strong and reliable information of the vaccine’s actual performance. The study’s conclusions have been supported by the UK Health Security Agency as showing robust protection for newborns during their most critical early weeks. The scope of this study provides healthcare professionals and expectant parents with assurance in the vaccine’s demonstrated effectiveness across different groups and contexts.
The results reveal a compelling picture of the vaccine’s ability to protect. More than 4,500 babies were hospitalised with RSV during the study period, with the vast majority being infants whose mothers had not been given the vaccination. This clear distinction highlights the vaccine’s vital importance in preventing serious illness in newborns. The drop in hospital admissions above 80 per cent represents a significant public health achievement, possibly preventing thousands of infants from experiencing the alarming and potentially severe symptoms connected with severe RSV infection. These findings support the importance of the vaccination programme established in the UK in 2024.
Methodology and scope of study
The research examined birth and hospitalisation records from England over a six-month period, capturing data on approximately 90% of all births during this timeframe. By examining around 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were in a position to determine direct comparisons of RSV infection rates and hospitalisations. The sizeable sample and comprehensive nature of the data gathering ensured that findings were statistically robust and reflective of the wider population, rather than isolated cases or limited subgroups.
The study specifically tracked hospital admissions for RSV among infants born to mothers who had been given the vaccine at differing periods before delivery. This allowed researchers to determine the shortest interval needed between vaccination and birth for best possible protection, as well as to determine whether protection remained meaningful with briefer timeframes. The methodology assessed real-world outcomes rather than laboratory-based settings, providing practical evidence of how the vaccine performs when delivered across varied healthcare environments and patient circumstances throughout the final three months of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Comprehending RSV and its threats
Respiratory syncytial virus, commonly referred to as RSV, is among the primary causes of hospital admission in infants aged under twelve months across the United Kingdom. The virus affects roughly fifty per cent of all newborns during their early months of life, with severity varying dramatically from mild cold-like symptoms to severe, life-threatening chest infections. More than 20,000 babies require intensive hospital care for RSV annually in the UK alone, placing considerable pressure on paediatric wards and neonatal units during busier periods.
The infection causes inflammation deep within the lungs and airways, making it extremely challenging for infected babies to feed and breathe adequately. Parents commonly see their babies fighting for breath, their chests heaving as they try to pull sufficient oxygen into their weakened respiratory system. Whilst most newborns recover with palliative treatment, a small but significant number die from RSV complications annually, making vaccination as prevention a essential public health priority for protecting the youngest and most vulnerable individuals in the population.
- RSV produces lung inflammation, leading to serious respiratory problems in babies
- Nearly 50% of infants acquire the virus during their first few months alive
- Symptoms span from minor cold-like symptoms to life-threatening chest infections requiring hospitalisation
- Over 20,000 UK infants require serious hospital care for RSV annually
- Few babies die from RSV related complications each year in the UK
Adoption rates and expert recommendations
Since the RSV vaccine programme commenced in 2024, health officials have highlighted the significance of pregnant women getting their jab at the ideal time for peak protection. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, has stressed that timing is crucial for ensuring newborns receive the most robust immunity from birth. Whilst the study demonstrates that vaccination at least four weeks before delivery provides approximately 85% protection, experts encourage women to get their vaccine as soon as feasible from 28 weeks of pregnancy onwards to maximise the antibodies passed to their babies via the placenta.
The communication from health authorities stays clear: pregnant women should make a priority of getting vaccinated during their third trimester, even if circumstances mean they cannot receive the jab at the best timing. Dr Watson has reassured expectant mothers that protection remains still achievable with reduced timeframes between immunisation and delivery, including even a fourteen-day window for those delivering slightly early. This flexible approach recognises the practical demands of pregnancy whilst maintaining strong protection for at-risk infants during their most critical early months when RSV poses the greatest risk of serious illness.
Regional differences in vaccine uptake
Whilst the RSV vaccine programme has been rolled out across England, uptake rates and deployment schedules have differed across different regions and NHS trusts. Certain regions have achieved higher vaccination coverage among qualifying expectant mothers, whilst others continue working to increase awareness and access to the jab. These geographical variations reflect variations in medical facilities, communication strategies, and community involvement initiatives, though the national data shows consistently strong protection irrespective of geographical location.
- NHS trusts rolling out multiple messaging strategies to connect with women during pregnancy
- Inconsistencies across regions in immunisation take-up across England demand focused enhancement
- Regional health providers adapting programmes to align with community needs and circumstances
Real-world impact and parental perspectives
The vaccine’s remarkable effectiveness provides real advantages for families throughout the United Kingdom. With over 20,000 babies admitted to hospital annually due to RSV prior to the introduction of this safeguarding intervention, the 80% drop in admissions means thousands of infants protected against severe infection. Parents no more face the upsetting situation of seeing their babies labour to breathe or struggle to eat, symptoms that define severe RSV infections. The vaccine has fundamentally shifted the picture of neonatal respiratory health, providing expectant mothers a active means to safeguard their most vulnerable children during those vital initial period.
For families like that of Malachi, whose acute RSV infection resulted in profound brain damage, the vaccine’s availability carries deep personal significance. His mother’s advocacy for the jab highlights the life-altering consequences that preventable illness can cause to young children and their families. Whilst Malachi’s experience predates the vaccine programme, his story resonates powerfully with parents now offered protection. The knowledge that such serious complications—hospital stay, oxygen dependency, neurological damage—are now largely preventable has provided considerable reassurance to women in pregnancy navigating their final trimester, changing what was once an predictable seasonal threat into a manageable health risk.